Earnings ·
Regeneron reports Q3 revenue of $5.1B and declares $0.94 quarterly dividend
REGNRegeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals reported third-quarter 2026 total revenues of $5.1 billion, a 36% increase from the prior year period. GAAP diluted EPS rose 35% to $18.45, while non-GAAP diluted EPS increased 70% to $20.07. The company declared a quarterly cash dividend of $0.94 per share, payable on December 3, 2026, to shareholders of record as of November 20, 2026. Additionally, Regeneron expanded its collaboration with Sanofi, receiving a $1.0 billion up-front payment for next-generation immunology antibodies. The biotechnology company invents, develops, and commercializes life-transforming medicines for serious diseases.